

Yusuf A Rajabally

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5827469/publications.pdf>

Version: 2024-02-01

167
papers

3,865
citations

186209

28
h-index

175177

52
g-index

169
all docs

169
docs citations

169
times ranked

3078
citing authors

#	ARTICLE	IF	CITATIONS
1	Regional variation of Guillain-Barré syndrome. <i>Brain</i> , 2018, 141, 2866-2877.	3.7	190
2	European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. <i>Journal of the Peripheral Nervous System</i> , 2021, 26, 242-268.	1.4	176
3	Outcome and its predictors in Guillain-Barré syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 711-718.	0.9	169
4	Electrophysiological diagnosis of Guillain-Barré syndrome subtype: could a single study suffice?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 115-119.	0.9	157
5	European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. <i>European Journal of Neurology</i> , 2021, 28, 3556-3583.	1.7	153
6	Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 1364-1368.	0.9	129
7	Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: Study of a UK population. <i>Muscle and Nerve</i> , 2009, 39, 432-438.	1.0	128
8	Neuropathy in Parkinson disease. <i>Neurology</i> , 2011, 77, 1947-1950.	1.5	109
9	Lewis-Sumner syndrome of pure upper limb onset: Diagnostic, prognostic, and therapeutic features. <i>Muscle and Nerve</i> , 2009, 39, 206-220.	1.0	89
10	CIDP and other inflammatory neuropathies in diabetes—diagnosis and management. <i>Nature Reviews Neurology</i> , 2017, 13, 599-611.	4.9	73
11	Current Proposed Mechanisms of Action of Intravenous Immunoglobulins in Inflammatory Neuropathies. <i>Current Neuropharmacology</i> , 2009, 7, 337-342.	1.4	69
12	Neuropathy and paraproteins: review of a complex association. <i>European Journal of Neurology</i> , 2011, 18, 1291-1298.	1.7	65
13	Identification of novel and recurrent CACNA1A gene mutations in fifteen patients with episodic ataxia type 2. <i>Journal of the Neurological Sciences</i> , 2010, 291, 30-36.	0.3	63
14	Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera. <i>Journal of Neurology</i> , 2020, 267, 3664-3672.	1.8	63
15	Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: A two-year study. <i>Journal of the Neurological Sciences</i> , 2011, 308, 124-127.	0.3	62
16	A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies. <i>Journal of the Peripheral Nervous System</i> , 2016, 21, 33-37.	1.4	59
17	Hereditary and inflammatory neuropathies: a review of reported associations, mimics and misdiagnoses. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1051-1060.	0.9	53
18	Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy. <i>Journal of the Peripheral Nervous System</i> , 2006, 11, 325-329.	1.4	50

#	ARTICLE	IF	CITATIONS
19	Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15. <i>Journal of Neuroinflammation</i> , 2017, 14, 224.	3.1	50
20	Optimizing the use of electrophysiology in the diagnosis of chronic inflammatory demyelinating polyneuropathy: a study of 20 cases. <i>Journal of the Peripheral Nervous System</i> , 2005, 10, 282-292.	1.4	48
21	Prospective study of <i>POLG</i> mutations presenting in children with intractable epilepsy: Prevalence and clinical features. <i>Epilepsia</i> , 2013, 54, 1002-1011.	2.6	42
22	Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens?. <i>Journal of Neurology</i> , 2013, 260, 2052-2056.	1.8	40
23	In Vivo Morphology of the Optic Nerve and Retina in Patients With Parkinson's Disease. , 2016, 57, 4420.		38
24	Electrophysiological features of chronic inflammatory demyelinating polyradiculoneuropathy associated with IgG4 antibodies targeting neurofascin 155 or contactin 1 glycoproteins. <i>Clinical Neurophysiology</i> , 2020, 131, 921-927.	0.7	34
25	Hypokalemic periodic paralysis associated with malignant hyperthermia. <i>Muscle and Nerve</i> , 2002, 25, 453-455.	1.0	33
26	Levodopa, vitamins, ageing and the neuropathy of Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 2844-2848.	1.8	33
27	Long-term Immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy. <i>Muscle and Nerve</i> , 2015, 51, 657-661.	1.0	33
28	The value of sensory electrophysiology in chronic inflammatory demyelinating polyneuropathy. <i>Clinical Neurophysiology</i> , 2007, 118, 1999-2004.	0.7	32
29	Median nerve ultrasonography in distinguishing neuropathy sub-types: a pilot study. <i>Acta Neurologica Scandinavica</i> , 2012, 125, 254-259.	1.0	31
30	Hereditary neuropathy with liability to pressure palsies. <i>Journal of Neurology</i> , 2020, 267, 2198-2206.	1.8	31
31	Chronic inflammatory demyelinating polyneuropathy and malignancy: A systematic review. <i>Muscle and Nerve</i> , 2018, 57, 875-883.	1.0	30
32	Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy. <i>Journal of Neurology</i> , 2019, 266, 461-467.	1.8	30
33	Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy. <i>Brain</i> , 2020, 143, 3214-3224.	3.7	30
34	Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	3.1	30
35	Disorder resembling Guillain-Barré syndrome on initiation of statin therapy. <i>Muscle and Nerve</i> , 2004, 30, 663-666.	1.0	29
36	Proximal nerve conduction studies in chronic inflammatory demyelinating polyneuropathy. <i>Clinical Neurophysiology</i> , 2006, 117, 2079-2084.	0.7	29

#	ARTICLE	IF	CITATIONS
37	Chronic inflammatory demyelinating polyneuropathy-like disorder associated with amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2008, 38, 855-860.	1.0	29
38	Guillain-Barré syndrome subtype diagnosis: A prospective multicentric European study. <i>Muscle and Nerve</i> , 2018, 58, 23-28.	1.0	29
39	Chronic inflammatory demyelinating polyradiculoneuropathy. <i>Presse Medicale</i> , 2013, 42, e203-e215.	0.8	28
40	Which criteria for research in chronic inflammatory demyelinating polyradiculoneuropathy? an analysis of current practice. <i>Muscle and Nerve</i> , 2015, 51, 932-933.	1.0	28
41	Neuropathy and impaired glucose tolerance: an updated review of the evidence. <i>Acta Neurologica Scandinavica</i> , 2011, 124, 1-8.	1.0	27
42	Chronic Inflammatory Pure Sensory Polyradiculoneuropathy. <i>Journal of Clinical Neuromuscular Disease</i> , 2012, 13, 149-152.	0.3	27
43	Restless legs syndrome in chronic inflammatory demyelinating polyneuropathy. <i>Muscle and Nerve</i> , 2010, 42, 252-256.	1.0	26
44	Distribution, clinical correlates and significance of axonal loss and demyelination in chronic inflammatory demyelinating polyneuropathy. <i>European Journal of Neurology</i> , 2011, 18, 293-299.	1.7	25
45	Chronic inflammatory demyelinating polyneuropathy caused by HIV infection in a patient with asymptomatic CMT 1A. <i>Journal of the Peripheral Nervous System</i> , 2000, 5, 158-162.	1.4	24
46	Hemicrania Continua Responsive to Verapamil. <i>Headache</i> , 2005, 45, 1082-1083.	1.8	24
47	A European multicentre reappraisal of distal compound muscle action potential duration in chronic inflammatory demyelinating polyneuropathy. <i>European Journal of Neurology</i> , 2012, 19, 638-642.	1.7	24
48	Effects of low frequency filtering on distal compound muscle action potential duration for diagnosis of CIDP: A Japanese-European multicenter prospective study. <i>Clinical Neurophysiology</i> , 2015, 126, 1805-1810.	0.7	24
49	Diagnostic value of MR imaging in the Lewis-Sumner syndrome: A case series. <i>Journal of the Neurological Sciences</i> , 2014, 342, 182-185.	0.3	23
50	Acute motor conduction block neuropathy followed by axonal degeneration and poor recovery. <i>Neurology</i> , 2006, 66, 287-288.	1.5	22
51	Rapidly Progressive Bilateral Ophthalmoplegia and Enlarging Sellar Mass Caused by Amelanotic Melanoma. <i>Journal of Neuro-Ophthalmology</i> , 2006, 26, 49-50.	0.4	21
52	Steroid-Responsive Paraneoplastic Demyelinating Neuropathy and Myelopathy Associated With Breast Carcinoma. <i>Journal of Clinical Neuromuscular Disease</i> , 2008, 10, 65-69.	0.3	21
53	Motor and sensory conduction failure in overlap of Guillain-Barré and Miller Fisher syndrome: Two simultaneous cases. <i>Journal of the Neurological Sciences</i> , 2011, 303, 35-38.	0.3	21
54	Jamar hand-held grip dynamometry in chronic inflammatory demyelinating polyneuropathy. <i>Journal of the Neurological Sciences</i> , 2013, 325, 36-38.	0.3	21

#	ARTICLE	IF	CITATIONS
55	Acute-onset polyradiculoneuropathy after <scp>SARS-CoV2</scp> vaccine in the West and North Midlands, United Kingdom. <i>Muscle and Nerve</i> , 2022, 65, 233-237.	1.0	21
56	Practical electrodiagnostic value of F-wave studies in chronic inflammatory demyelinating polyneuropathy. <i>Clinical Neurophysiology</i> , 2013, 124, 171-175.	0.7	20
57	Chronic inflammatory demyelinating polyneuropathy associated with diabetes: a European multicentre comparative reappraisal. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1100-1104.	0.9	20
58	Insulin Neuritis and Diabetic Cachectic Neuropathy: A Review. <i>Current Diabetes Reviews</i> , 2013, 9, 267-274.	0.6	20
59	Management challenges for chronic dysimmune neuropathies during the <scp>COVID</scp>-19 pandemic. <i>Muscle and Nerve</i> , 2020, 62, 34-40.	1.0	19
60	Electrophysiological sensory demyelination in typical chronic inflammatory demyelinating polyneuropathy. <i>European Journal of Neurology</i> , 2010, 17, 939-944.	1.7	18
61	Common and Less Common Peripheral Nerve Disorders Associated with Diabetes. <i>Current Diabetes Reviews</i> , 2012, 8, 229-236.	0.6	18
62	Hyponatraemia in Guillain-Barré syndrome revisited. <i>Acta Neurologica Scandinavica</i> , 2016, 133, 295-301.	1.0	18
63	Neuropsychiatric manifestations in inflammatory neuropathies: A systematic review. <i>Muscle and Nerve</i> , 2016, 54, 1-8.	1.0	18
64	Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: evidence base and clinical practice. <i>Acta Neurologica Scandinavica</i> , 2016, 133, 228-238.	1.0	18
65	Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins. <i>Biologics: Targets and Therapy</i> , 2010, 4, 45.	3.0	17
66	Health-related quality of life in chronic inflammatory neuropathies: A systematic review. <i>Journal of the Neurological Sciences</i> , 2015, 348, 18-23.	0.3	17
67	Determinants of health-related quality of life in anti-MAG neuropathy: a cross-sectional multicentre European study. <i>Journal of the Peripheral Nervous System</i> , 2017, 22, 27-33.	1.4	17
68	Dyslipidaemia in chronic acquired distal axonal polyneuropathy. <i>Journal of Neurology</i> , 2011, 258, 1431-1436.	1.8	16
69	Sural sparing in Guillain-Barré syndrome subtypes: a reappraisal with historical and recent definitions. <i>Clinical Neurophysiology</i> , 2016, 127, 1683-1688.	0.7	16
70	Malignancy in Guillain-Barré syndrome: A twelve-year single-center study. <i>Journal of the Neurological Sciences</i> , 2017, 375, 275-278.	0.3	16
71	Unconventional treatments for chronic inflammatory demyelinating polyneuropathy. <i>Neurodegenerative Disease Management</i> , 2017, 7, 331-342.	1.2	16
72	Prevalence, correlates and impact of pain and cramps in anti-MAG neuropathy: a multicentre European study. <i>European Journal of Neurology</i> , 2018, 25, 135-141.	1.7	16

#	ARTICLE	IF	CITATIONS
73	Comparative value and determinants of suitability of outcome measures in treated chronic inflammatory demyelinating polyneuropathy. <i>Muscle and Nerve</i> , 2020, 61, 182-186.	1.0	16
74	Demyelinating neuropathy with anti- α -CRMP5 antibodies predating diagnosis of breast carcinoma: Favorable outcome after cancer therapy. <i>Muscle and Nerve</i> , 2011, 43, 764-766.	1.0	15
75	No association between neuropathy and restless legs in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2013, 127, 216-220.	1.0	15
76	Facial Onset Sensory Motor Neuronopathy. <i>Journal of Clinical Neuromuscular Disease</i> , 2013, 14, 176-179.	0.3	15
77	Optic and auditory pathway dysfunction in demyelinating neuropathies. <i>Acta Neurologica Scandinavica</i> , 2014, 130, 53-57.	1.0	15
78	Motor unit number index (MUNIX) in chronic inflammatory demyelinating polyneuropathy: A potential role in monitoring response to intravenous immunoglobulins. <i>Clinical Neurophysiology</i> , 2019, 130, 1743-1749.	0.7	15
79	Hemiplegic ALS: Mills syndrome. <i>Neurology</i> , 2005, 64, 1984-1985.	1.5	14
80	Electrophysiological markers of large fibre sensory neuropathy: a study of sensory and motor conduction parameters. <i>European Journal of Neurology</i> , 2009, 16, 1053-1059.	1.7	14
81	Value of distal compound muscle action potential duration prolongation in acute inflammatory demyelinating polyneuropathy: A European perspective. <i>Muscle and Nerve</i> , 2011, 43, 751-755.	1.0	14
82	Influence of timing on electrodiagnosis of Guillain-Barré syndrome in the first six weeks: A retrospective study. <i>Journal of the Neurological Sciences</i> , 2015, 357, 143-145.	0.3	14
83	Outcome measures for chronic inflammatory demyelinating polyneuropathy in research: relevance and applicability to clinical practice. <i>Neurodegenerative Disease Management</i> , 2019, 9, 259-266.	1.2	14
84	Small fiber neuropathy in unexpected clinical settings: a review. <i>Muscle and Nerve</i> , 2020, 62, 167-175.	1.0	14
85	Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy. <i>Journal of Neurology</i> , 2021, 268, 1366-1373.	1.8	14
86	Oro-Mandibular Dystonia in a Case of Multiple Sclerosis with Capsular Plaque. <i>European Neurology</i> , 2003, 49, 190-191.	0.6	13
87	Sensorimotor Guillain-Barré syndrome with anti-GD1b antibodies following influenza A infection. <i>European Journal of Neurology</i> , 2009, 16, e81.	1.7	13
88	Minimal important differences and self-identifying treatment response in chronic inflammatory demyelinating polyneuropathy. <i>Muscle and Nerve</i> , 2021, 64, 37-42.	1.0	13
89	Neuropathy associated with lansoprazole treatment. <i>Muscle and Nerve</i> , 2005, 31, 124-125.	1.0	12
90	Optimizing electrodiagnosis for Guillain-Barré syndrome: Clues from clinical practice. <i>Muscle and Nerve</i> , 2017, 55, 748-751.	1.0	12

#	ARTICLE	IF	CITATIONS
91	Electrophysiological entrapment syndromes in chronic inflammatory demyelinating polyneuropathy. <i>Muscle and Nerve</i> , 2011, 44, 444-447.	1.0	11
92	Optic neuropathy associated with CANOMAD: Description of 2 cases. <i>Muscle and Nerve</i> , 2011, 44, 451-455.	1.0	11
93	Clinical correlates of fatigue in chronic inflammatory demyelinating polyneuropathy. <i>Muscle and Nerve</i> , 2020, 62, 226-232.	1.0	11
94	Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC). <i>Trials</i> , 2021, 22, 155.	0.7	11
95	Antecedent infections and vaccinations in chronic inflammatory demyelinating polyneuropathy: A European collaborative study. <i>Muscle and Nerve</i> , 2021, 64, 657-661.	1.0	11
96	Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome. <i>Neurotherapeutics</i> , 2022, 19, 885-896.	2.1	11
97	Chronic inflammatory demyelinating polyneuropathy after <i>Campylobacter jejuni</i> infection mimicking vasculitic mononeuritis multiplex in a diabetic. <i>Journal of the Peripheral Nervous System</i> , 2004, 9, 98-103.	1.4	10
98	Treatment of Guillain-Barre Syndrome: A Review. <i>Inflammation and Allergy: Drug Targets</i> , 2012, 11, 330-334.	1.8	10
99	231st ENMC International Workshop: Neuromuscular Disorders, 2018, 28, 178-184.	0.3	10
100	Complications of Immunoglobulin Therapy and Implications for Treatment of Inflammatory Neuropathy: A Review. <i>Current Drug Safety</i> , 2019, 14, 3-13.	0.3	10
101	Clinical heterogeneity in mild chronic inflammatory demyelinating polyneuropathy. <i>European Journal of Neurology</i> , 2006, 13, 958-962.	1.7	9
102	Juvenile myoclonic epilepsy in an elderly patient. <i>Age and Ageing</i> , 2006, 35, 194-196.	0.7	9
103	Immunoglobulin-responsive dysautonomia in Sjögren's syndrome. <i>Journal of Neurology</i> , 2007, 254, 674-675.	1.8	9
104	Electrophysiological predictors of steroidresponsiveness in chronic inflammatory demyelinating polyneuropathy. <i>Journal of Neurology</i> , 2008, 255, 936-938.	1.8	9
105	Characteristics and correlates of sensory function in chronic inflammatory demyelinating polyneuropathy. <i>Journal of the Neurological Sciences</i> , 2010, 297, 11-14.	0.3	9
106	Severe but reversible neuropathy and encephalopathy due to vitamin E deficiency. <i>Clinical Neurology and Neurosurgery</i> , 2017, 160, 19-20.	0.6	9
107	Serial electrophysiology in Guillain-Barré syndrome: A retrospective cohort and case-by-case multicentre analysis. <i>Acta Neurologica Scandinavica</i> , 2018, 137, 335-340.	1.0	9
108	Acute neuropathy and erythromelalgia following topical exposure to isopropanol. <i>Veterinary and Human Toxicology</i> , 2004, 46, 24-5.	0.3	9

#	ARTICLE	IF	CITATIONS
109	Paraneoplastic brainstem encephalitis with tetraparesis in a patient with anti-Ri antibodies. <i>Journal of Neurology</i> , 2004, 251, 1528-1529.	1.8	8
110	Circulating Folate Concentrations and Risk of Peripheral Neuropathy and Mortality: A Retrospective Cohort Study in the U.K. <i>Nutrients</i> , 2019, 11, 2443.	1.7	8
111	Anti-GM1 antibody-negative acute motor axonal neuropathy after <i>Mycoplasma pneumoniae</i> infection. <i>European Journal of Neurology</i> , 2006, 13, 95-96.	1.7	7
112	Knowledge of TIA among general practitioners and emergency department physicians. A questionnaire survey in a French semi-rural area. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1457-1463.	0.6	7
113	Disease status in chronic inflammatory demyelinating polyneuropathy: inter-centre comparative analysis and correlates. <i>European Journal of Neurology</i> , 2015, 22, 1469-1473.	1.7	7
114	Newer anti-epileptic drugs, vitamin status and neuropathy: A cross-sectional analysis. <i>Revue Neurologique</i> , 2017, 173, 62-66.	0.6	7
115	Tailoring of therapy for chronic inflammatory demyelinating polyneuropathy. <i>Neural Regeneration Research</i> , 2015, 10, 1399.	1.6	7
116	Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. <i>Clinical Neurophysiology</i> , 2022, 138, 231-240.	0.7	7
117	Intracranial Hypertension Induced by Rofecoxib. <i>Headache</i> , 2005, 45, 75-76.	1.8	6
118	Elderly patients with epileptic seizures: In-patient observational study of two French community hospitals. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2011, 20, 231-239.	0.9	6
119	Chronic inflammatory demyelinating polyneuropathy associated with alopecia totalis and Sjögren syndrome. <i>Muscle and Nerve</i> , 2012, 45, 762-763.	1.0	6
120	Restless legs syndrome in sensory axonal neuropathy: A case-control study. <i>Revue Neurologique</i> , 2013, 169, 228-233.	0.6	6
121	Patient perceptions of outcome measures in chronic inflammatory demyelinating polyneuropathy: A study of the Inflammatory Rasch-built Overall Disability Scale. <i>European Journal of Neurology</i> , 2021, 28, 2596-2602.	1.7	6
122	Causes and consequences of diagnostic delay in <sc>Guillain-Barré</sc> syndrome in a UK tertiary center. <i>Muscle and Nerve</i> , 2022, 65, 547-552.	1.0	6
123	Bilateral meralgia paraesthetica following repeated laparotomies. <i>European Journal of Neurology</i> , 2003, 10, 330-331.	1.7	5
124	Brachial diplegia as a result of cervical cord injury. <i>Spinal Cord</i> , 2005, 43, 389-391.	0.9	5
125	Multifocal motor neuropathy: review of a treatable immune mediated disorder. <i>Postgraduate Medical Journal</i> , 2008, 84, 287-292.	0.9	5
126	IqYmune® is an effective maintenance treatment for multifocal motor neuropathy: A randomised, double-blind, multi-center cross-over non-inferiority study vs Kiovig®. The LIME Study. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 56-63.	1.4	5

#	ARTICLE	IF	CITATIONS
127	<p>Evolving Immunologic Perspectives in Chronic Inflammatory Demyelinating Polyneuropathy</p>. Journal of Inflammation Research, 2020, Volume 13, 543-549.	1.6	5
128	The â€œchronic immune polyradiculopathiesâ€: Diverse but maybe just <scp>CIDP</scp> after all. Muscle and Nerve, 2021, 63, 7-9.	1.0	5
129	Neuroleptic malignant syndrome and acute motor axonal neuropathy after Campylobacter jejuni infection. Neurophysiologie Clinique, 2009, 39, 135-138.	1.0	4
130	Diagnosis, epidemiology and treatment of inflammatory neuropathies. British Journal of Hospital Medicine (London, England: 2005), 2012, 73, 380-385.	0.2	4
131	New insights into the management of chronic inflammatory demyelinating polyradiculoneuropathy. Neurodegenerative Disease Management, 2015, 5, 257-268.	1.2	4
132	Assessing the benefit of treatment in chronic inflammatory demyelinating polyneuropathy: the challenges of clinical practice. Neurodegenerative Disease Management, 2018, 8, 285-288.	1.2	4
133	Compliance with international guidelines for chronic inflammatory neuropathies. European Journal of Neurology, 2019, 26, 557-558.	1.7	4
134	Iatrogenic immune-mediated neuropathies: diagnostic, epidemiological and mechanistic uncertainties for causality and implications for clinical practice. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 975-982.	0.9	4
135	Immunomodulation in Inflammatory Neuropathies: Rationale and Safety. Current Drug Safety, 2013, 8, 225-235.	0.3	4
136	The value of <scp>MUNIX</scp> as an objective electrophysiological biomarker of disease progression in chronic inflammatory demyelinating polyneuropathy. Muscle and Nerve, 2022, 65, 433-439.	1.0	4
137	Neuropathies in the older patient. Reviews in Clinical Gerontology, 2006, 16, 113-124.	0.5	3
138	Charcot-Marie-Tooth Disease due to Novel Myelin Protein Zero Mutation Presenting as Late-Onset Remitting Sensory Neuropathy. Journal of Clinical Neuromuscular Disease, 2010, 11, 187-190.	0.3	3
139	Steroid-Induced Inflammatory Neuropathy in a Patient on Tumor Necrosis Factor-Î± Antagonist Therapy. Journal of Clinical Neuromuscular Disease, 2010, 12, 88-90.	0.3	3
140	A Rare Cause of Late-Onset Cerebellar Ataxia: Erdheimâ€™s Chester Disease. Cerebellum, 2013, 12, 593-595.	1.4	3
141	Compound muscle action potential amplitude and distal potential duration in axonal neuropathy. Muscle and Nerve, 2014, 49, 146-147.	1.0	3
142	Retrospective analysis of response to rituximab in chronic inflammatory demyelinating polyneuropathy refractory to firstâ€™line therapy. Journal of the Peripheral Nervous System, 2021, 26, 469-474.	1.4	3
143	Charcot-Marie-Tooth disease type 1A associated with acute porphyric neuropathy. European Journal of Neurology, 2007, 14, e10-e11.	1.7	2
144	Novel Therapeutic Avenues for Chronic Inflammatory Demyelinating Polyneuropathy: The Difficulties of Disease Diversity. EBioMedicine, 2016, 6, 12-13.	2.7	2

#	ARTICLE	IF	CITATIONS
145	Chronic inflammatory demyelinating polyneuropathy misdiagnosis: A clinical more than electrophysiological problem?. Muscle and Nerve, 2018, 57, E131-E132.	1.0	2
146	Autoantibodies in the diagnostic work-up of neuropathy: clinically useful or purely academic?. British Journal of Hospital Medicine (London, England: 2005), 2020, 81, 1-9.	0.2	2
147	Chronic inflammatory demyelinating polyneuropathy. , 2020, , 31-83.		2
148	The value of new tests: Magnetic resonance imaging for dysimmune neuropathy. Muscle and Nerve, 2020, 61, 677-678.	1.0	2
149	The value of ultrasonography versus clinical examination in differentiating acute inflammatory demyelinating polyneuropathy from acute-onset chronic inflammatory demyelinating polyneuropathy: The importance of timing. Muscle and Nerve, 2015, 51, 459-459.	1.0	1
150	Cost of illness, cost of immunoglobulin therapy and their determinants in chronic inflammatory demyelinating polyneuropathy. Muscle and Nerve, 2019, 59, E22.	1.0	1
151	Peripheral nerve electrophysiology studies in relation to fatigue in patients with chronic inflammatory demyelinating polyneuropathy. Clinical Neurophysiology, 2020, 131, 2926-2931.	0.7	1
152	Electrophysiology in CIDP: Should we use it beyond diagnosis?. Clinical Neurophysiology, 2021, 132, 204-206.	0.7	1
153	Successful treatment of indomethacin-intolerant chronic paroxysmal hemicrania: report of two cases. Journal of Headache and Pain, 2003, 4, 168-170.	2.5	0
154	Intracranial Hypertension Associated With Transverse Myelitis. Journal of Neuro-Ophthalmology, 2004, 24, 344-345.	0.4	0
155	Multi-focal motor neuropathy: one treatment works but many uncertainties remain. Expert Opinion on Biological Therapy, 2011, 11, 257-259.	1.4	0
156	Plasmapheresis is Effective for Respiratory Failure in Hashimoto's Encephalopathy. Journal of the Intensive Care Society, 2012, 13, 174-175.	1.1	0
157	Reply:. Muscle and Nerve, 2015, 52, 916-916.	1.0	0
158	Testing nerves: an overview of investigations for neuropathy. British Journal of Hospital Medicine (London, England: 2005), 2016, 77, 508-515.	0.2	0
159	A case of POEMS mimicking a "Guillain-Barré" like syndrome. Journal of the Neurological Sciences, 2016, 369, 268-270.	0.3	0
160	Poems and "MGUS" related neuropathy" Electrophysiologically different but in many ways. Muscle and Nerve, 2017, 56, E175-E176.	1.0	0
161	Burden of illness in chronic inflammatory demyelinating polyneuropathy: some facts and solutions. Journal of Neurology, 2020, 267, 3092-3093.	1.8	0
162	To treat or not to treat mild Guillain-Barré syndrome: limited evidence for but still none against. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1027-1028.	0.9	0

#	ARTICLE	IF	CITATIONS
163	Autoantibodies in the diagnostic work-up of neuropathy: clinically useful or purely academic?. British Journal of Neuroscience Nursing, 2021, 17, 84-89.	0.1	0
164	A diabetic patient with recurrent tetraparesis. Journal of the Royal Society of Medicine, 2003, 96, 351-352.	1.1	0
165	Contemporary challenges in the diagnosis and management of chronic inflammatory demyelinating polyneuropathy. Expert Review of Neurotherapeutics, 2022, 22, 89-99.	1.4	0
166	Evidence base for investigative and therapeutic modalities in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. Neurodegenerative Disease Management, 2022, 12, 35-47.	1.2	0
167	Electrophysiology to identify disease mechanisms in <scp>CIDP</scp> : Reliability and value. Muscle and Nerve, 0, , .	1.0	0